MIAMI , Dec. 20, 2024 /PRNewswire/ -- Hyatt Centric South Beach Miami is proud to announce the completion of its highly anticipated renovations, redefining luxury and sophistication in the heart of South Beach at 1600 Collins Ave, Miami Beach, FL 33139. Designed by Lang & Schwander to embody the vibrant energy and upscale charm of Miami , the updates include newly reimagined rooms and suites, check-in lobby, inclusivity spaces, from food and beverage and communal lounge areas that celebrate the hotel's commitment to connecting guests to the pulse of the city. Elevated Rooms and Suites The newly renovated 105 guest rooms and suites blend modern design with thoughtful functionality. Each space is adorned with sleek furnishings, neutral tones, and vibrant accents inspired by Miami's art scene. Enhanced amenities include plush bedding, state-of-the-art technology, and expansive windows offering stunning views of South Beach's iconic skyline and coastline. Enhanced Check-In Lobby and Inclusivity Spaces Guests are greeted with an upgraded check-in lobby on the third floor that exudes warmth and style. Featuring contemporary decor and comfortable seating, the space serves as an inviting prelude to their South Beach experience. Communal areas have also been reimagined to foster connection, offering vibrant social spaces. From a chic full bar serving classic and unique cocktails, to indoor communal lounge area to serene outdoor terraces, Hyatt Centric South Beach Miami provides the perfect setting to connect and recharge with fellow travelers. Unparalleled Amenities Hyatt Centric South Beach Miami continues to deliver exceptional amenities that cater to modern travelers. Guests can enjoy: "Hyatt Centric South Beach Miami has always been envisioned as a destination where the vibrant spirit of South Beach meets unparalleled hospitality. Our recent renovations mark the next chapter in our dedication to elevating guest experiences and showcasing the beauty and culture of Miami Beach ," said Robert Finvarb , Founder of Robert Finvarb Companies. Hyatt Centric South Beach Miami serves as the ultimate launchpad for adventure, offering guests access to the city's finest attractions, including Ocean Drive, Lincoln Road Mall, and the Art Deco Historic District. About Hyatt Centric Hyatt Centric is a brand of full-service lifestyle hotels located in prime destinations. Created to connect guests to the heart of the action, Hyatt Centric hotels are thoughtfully designed to enable exploration and discovery so they never miss a moment of adventure. Each hotel offers social spaces to connect with others in the lobby, meanwhile the bar and restaurant are local hot spots where great conversations, locally inspired food and signature cocktails can be enjoyed. Streamlined modern rooms focus on delivering everything guests want and nothing they don't. A passionately engaged team is there to provide local expertise on the best food, nightlife and activities the destination has to offer. For more information, please visit hyattcentric.com . Follow @HyattCentric on Facebook and Instagram , and tag photos with #HyattCentric. About Robert Finvarb Companies Hyatt Centric is a brand of full-service lifestyle hotels located in prime destinations. Created to connect guests to the heart of the action, Hyatt Centric hotels are thoughtfully designed to enable exploration and discovery so they never miss a moment of adventure. Each hotel offers social spaces to connect with others in the lobby, meanwhile the bar and restaurant are local hot spots where great conversations, locally inspired food and signature cocktails can be enjoyed. Streamlined modern rooms focus on delivering everything guests want and nothing they don't. A passionately engaged team is there to provide local expertise on the best food, nightlife and activities the destination has to offer. For more information, please visit hyattcentric.com . Follow @HyattCentric on Facebook and Instagram , and tag photos with #HyattCentric. About Robert Finvarb Companies Robert Finvarb Companies (RFC) is a private real estate investment and development company based in Miami, Florida . Robert Finvarb , founder of the company, started his development career in 2002. Since then, RFC has developed nineteen hotels containing an excess of 3,500 guestrooms that operate under various Marriott and Hyatt brands and are located in seven states and the District of Columbia . RFC has a reputation for developing high-quality assets and possesses a track record of success in all market cycles. As a private company, the principals invest their own equity in all projects and are personally involved in all phases of development and operations. For more than 20 years, RFC has carefully cultivated its reputation of excellence in the hospitality industry. RFC's team of development and lodging specialists have a wide-ranging expertise in real estate and capital markets that is applied in identifying accretive investment opportunities to maximize the financial performance of such projects. CONTACT: Jacqueline Mercado Hyatt Hotels Corporation + 1 786 578 6886 jacqueline@identitymediapr.com View original content to download multimedia: https://www.prnewswire.com/news-releases/new-year-new-look-hyatt-centric-south-beach-miami-debuts-elevated-style-and-luxury-302337669.html SOURCE Hyatt Centric South Beach Miami
Brown 83, Canisius 76Headed South for Winter? 5 Tips for Snowbirds About to Take Flight
49ers RBs Christian McCaffrey, Jordan Mason placed on IR(Reuters) - OpenAI said on Friday it was testing new reasoning AI models, o3 and o3 mini, in a sign of growing competition with rivals such as Google to create smarter models capable of tackling complex problems. CEO Sam Altman said the AI startup plans to launch o3 mini by the end of January, and full o3 after that, as more robust large language models could outperform existing models and attract new investments and users. Microsoft-backed OpenAI released o1 AI models in September designed to spend more time processing queries to solve hard problems. The o1 models are capable of reasoning through complex tasks and can solve more challenging problems than previous models in science, coding and math, the AI firm had said in a blog post. OpenAI's new o3 and o3 mini models, which are in internal safety testing currently, will be more powerful than its previously launched o1 models, the company said. The GenAI pioneer said it was opening up an application process for external researchers to test o3 models ahead of the public release, which will close on Jan. 10. OpenAI had triggered an AI arms race after it launched ChatGPT in November 2022. The growing popularity of the company and new product launches helped OpenAI in closing a $6.6 billion funding round in October. Rival Alphabet's Google released the second generation of its AI model Gemini earlier in December, as the search giant aims to reclaim the lead in the AI technology race. (Reporting by Jaspreet Singh in Bengaluru; Editing by Vijay Kishore)Is the NORAD Santa tracker safe from a government shutdown?
Amazon.com, Inc. (NASDAQ:AMZN) Shares Purchased by Highland Capital Management LLCBiliary Tract Cancer Pipeline Therapeutics Assessment Report 2024 (Updated) 11-30-2024 01:32 PM CET | Health & Medicine Press release from: DelveInsight Business Research LLP Biliary Tract Cancer Pipeline DelveInsight's, "Biliary Tract Cancers Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Biliary Tract Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Biliary Tract Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Biliary Tract Cancer Pipeline Report •In November 2024:- Unicancer- This is a Phase 3, multicentre, randomised, open-label trial to evaluate whether the introduction of molecular targeted therapy (MTT) as maintenance after 4 cycles of standard-of-care first-line systemic therapy (1L SoC) is superior to continuation of 1L-SoC in the treatment of patients with ABC. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, and (ii) a randomised comparative trial. •In November 2024:- AstraZeneca- A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers •DelveInsight's Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for treatment. •The leading Biliary Tract Cancer Companies such as Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others. •Promising Biliary Tract Cancer Therapies such as Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others. Stay ahead with the most recent pipeline outlook for Biliary Tract Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Biliary Tract Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Biliary Tract Cancer Emerging Drugs Profile •MRG 002: Miracogen MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle). •Disitamab vedotin: Yantai Rongchang Pharmaceutical Disitamab Vedotin is an antibody-drug conjugate with a drug structure consisting of three parts Anti-human epidermal growth factor receptor 2 extracellular domain (HER2 ECD) antibody; Linker (MC-Val-Cit-PAB, Linker); and Cytotoxic Monomethyl Auristatin E (Monomethyl Auristatin E, MMAE). This product is white to light yellow loose body, after reconstitution, it is colorless to light yellow clear liquid. •Envafolimab: Alphamab Oncology Envafolimab is a PD-L1 single-domain antibody Fc fusion protein independently developed by Alphamab. Based on the unique design, Envafolimab has advantages in safety, convenience and compliance, and can be used for patients who are not suitable for intravenous infusion with a lower medical cost. On March 30, 2020, Alphamab, 3D Medicines and Simcere reached a three-way strategic collaboration. Alphamab, as the original research party, is responsible for production and quality, 3D Medicines is responsible for global clinical development in the field of oncology, registration and commercialization abroad, and Simcere is responsible for the exclusive commercial promotion of the product in mainland China. •DKN-01: Leap Therapeutics DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. Explore groundbreaking therapies and clinical trials in the Biliary Tract Cancer Pipeline. Access DelveInsight's detailed report now! @ New Biliary Tract Cancer Drugs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration •Intravenous •Subcutaneous •Oral •Intramuscular Products have been categorized under various Molecule types such as •Monoclonal antibody •Small molecule •Peptide Unveil the future of Biliary Tract Cancer treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Biliary Tract Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Scope of the Biliary Tract Cancer Pipeline Report •Coverage- Global •Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination •Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III •Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others •Biliary Tract Cancer Therapies- Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others. Get the latest on Biliary Tract Cancer therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Biliary Tract Cancer Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Table of Content 1.Introduction 2.Executive Summary 3.Biliary Tract Cancer: Overview 4.Pipeline Therapeutics 5.Therapeutic Assessment 6.Biliary Tract Cancer- DelveInsight's Analytical Perspective 7.Late Stage Products (Phase III) 8.Envafolimab: Alphamab Oncology 9.Drug profiles in the detailed report..... 10.Mid Stage Products (Phase II/III) 11.SMT-NK: SMT bio Co., Ltd. 12.Drug profiles in the detailed report..... 13.Mid Stage Products (Phase II) 14.HA121-28: CSPC ZhongQi Pharmaceutical Technology 15.Drug profiles in the detailed report..... 16.Early Stage Products (Phase I) 17.ZKAB001: Lee's Pharmaceutical Limited 18.Drug profiles in the detailed report..... 19.Preclinical and Discovery Stage Products 20.Drug name: Company name 21.Drug profiles in the detailed report..... 22.Inactive Products 23.Biliary Tract Cancer Key Companies 24.Biliary Tract Cancer Key Products 25.Biliary Tract Cancer- Unmet Needs 26.Biliary Tract Cancer- Market Drivers and Barriers 27.Biliary Tract Cancer- Future Perspectives and Conclusion 28.Biliary Tract Cancer Analyst Views 29.Biliary Tract Cancer Key Companies 30.Appendix List of Top Selling Market Research Reports in 2024 carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market stem cell market- https://www.delveinsight.com/report-store/stem-cell-market surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: info@delveinsight.com Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.
10-man Botafogo wins its first Copa Libertadores title
TEMPE, Ariz. (AP) — Marcus Johnson scored 23 points and Javontae Campbell secured the victory with a free throw with 12 seconds remaining as Bowling Green knocked off New Mexico State 61-60 on Saturday. Johnson had five rebounds and three steals for the Falcons (3-5). Derrick Butler scored 15 points while going 4 of 15 from the floor, including 2 for 7 from 3-point range, and 5 for 5 from the line and added five rebounds. Campbell had 12 points and shot 1 of 9 from the field and 10 of 12 from the free-throw line. The Aggies (3-4) were led by Jaden Harris, who posted 18 points and nine rebounds. New Mexico State also got 10 points and seven rebounds from Robert Carpenter. Christian Cook finished with nine points and four assists. Campbell scored a team-high 12 points for Bowling Green in the second half, including their game-winner. NEXT UP Up next for Bowling Green is a Saturday matchup with Morgan State at home, and New Mexico State hosts Abilene Christian on Wednesday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Fianna Fail is the largest party in Ireland on 48 seats out of 174 in parliament, with Sinn Fein on 39 and Fine Gael on 38. Fianna Fail also secured the most first preference votes in Friday's vote, taking 21.9% to Fine Gael's 20.8%. Sinn Fein came in third on 19%. The result, after three days of counting, paves the way for a Fianna Fail-Fine Gael coalition in government with either a handful of independents or a third party. The two centre-right parties had previously said they would not rule with the left-wing Sinn Fein. Please use Chrome browser for a more accessible video player Their combined seat total of 86 would leave them just short of the 88 needed for a majority in the Dail. Entering a coalition with independents would likely involve fewer policy concessions and financial commitments than may be required to convince another party to join the government benches. Nine independents joined a Fine Gael-led minority government in 2016, with three serving in ministerial positions. The Social Democrats and the Irish Labour Party, both smaller left-wing parties, appear cautious about the prospect of an alliance with Fianna Fail and Fine Gael. The last coalition partner, the Green Party, lost 11 out of 12 seats in this election. While Sinn Fein appears to currently have no realistic route to government, its leader Mary Lou McDonald contacted the leaders of the Social Democrats and Labour on Monday to discuss options for forming a left-wing government. Earlier, Fianna Fail deputy leader and outgoing finance minister Jack Chambers predicted that a new coalition government would not be in place before Christmas. Read more: Why are generations divided on the economy? How Ireland voted in maps and charts Why did anti-immigration candidates do so badly? Mr Chambers said planned talks about forming an administration required "time and space" to ensure that any new government will be "coherent and stable". It took almost five months for Fianna Fail, Fine Gael and the Greens to form a government after the 2020 election. In that government, it was agreed that the leaders of the two larger parties would have a "rotating taoiseach" arrangement. Follow our channel and never miss an update Fianna Fail leader Michael Martin took the role for the first half of the term, with Leo Varadkar taking over in December 2022. Current Fine Gael leader Simon Harris succeeded Mr Varadkar as taoiseach when he resigned earlier this year. But as Fianna Fail has increased the number of seats it has over Fine Gael, it is unclear if this arrangement will continue. Be the first to get Breaking News Install the Sky News app for free Every government since the foundation of the state almost a century ago has been led by either Fianna Fail or Fine Gael, who are historic rivals with origins on opposing sides of Ireland's 1920s civil war.President-elect Donald Trump suggests the United States should control Canada, Greenland, and the Panama Canal, sparking strong reactions from the involved countries. "Because we're being ripped off at the Panama Canal like we're being ripped off everywhere else," Trump said. Trump argues that Panama charges "ridiculous" fees for using the canal and criticizes President Jimmy Carter for ceding control of the canal in a historic peace treaty. "I leave them there as totally irrelevant issues and quite bordering on historical incoherence with what the Panama Canal has been, is and will be," said José Raúl Mulino, the president of Panama, through a translator. Trump has also targeted Canada on social media, suggesting it should become the 51st state and referring to Prime Minister Justin Trudeau as a governor. "Canada allows people and drugs to flow in through our Northern Border," Trump said. Trump's comments have caused turmoil in Ottawa, leading to the resignation of the finance minister over disagreements on handling the new hostility. "What we need to do is make sure that we strengthen our relationships with our allies and treaty partners like Panama, not make ridiculous carnival barker threats," said Rep. Debbie Wasserman-Schultz, D-Florida. Trump also claims that U.S. control of Greenland is vital for "national security and freedom throughout the world." However, the Danish Prime Minister has stated that the territory is not for sale but is open for cooperation. During his first administration, Trump canceled a 2019 visit to Denmark after his initial offer to buy Greenland was rejected. This is not the first time a U.S. president has shown interest in Greenland; President Harry Truman offered to purchase it from Denmark in 1946 for $100 million in gold. President-elect Donald Trump on Wednesday announced Miami-Dade County Commissioner Kevin Cabrera as the ambassador to Panama.